Repligen announces acquisition of FlexBiosys for undisclosed cash, equity, and earnout

REPLIGEN CORP

Repligen executed Equity Purchase Agreement to acquire all outstanding equity of FlexBiosys.
Consideration comprises cash, equity, and performance-based earnout payments through year-end 2024.
Transaction expected to close in Q2 2023, subject to satisfaction of conditions.
No financial terms or valuation were disclosed in the SEC filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.